公开(公告)号：US20220251652A1

公开(公告)日：2022-08-11

申请号：US17436948

申请日：2020-03-06

Applicant: NEOGENTC CORP.

Inventor： Hee Jin Lee ,  Gyungyub GONG ,  Hee Jae Lee ,  Jeong Han Seo ,  Gyeongback Lim

IPC: C12Q1/6881 ,  C12Q1/6886

Abstract: The present invention relates to a marker for predicting a tumor reactivity of lymphocytes, a composition for predicting a tumor reactivity, and a method for predicting a tumor reactivity. Using the genetic marker according to the present invention, a predictive model that can predict the tumor reactivity of cultured lymphocytes may be constructed, and it is possible to more accurately select tumor-specific lymphocytes to produce an effective immunotherapeutic agent, by predicting the reactivity of the lymphocytes through the present invention. In addition, by using the above genetic markers, it is possible to more conveniently and non-invasively separate lymphocytes from body tissues, blood, or body fluids, deviating from the conventional invasive methods, and to select only lymphocytes with tumor-specific activity, for immunotherapy. It is expected to widely use with various application.